Detalhe da pesquisa
1.
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1334-1348, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039991
2.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Lancet Gastroenterol Hepatol
; 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38823398
3.
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
J Clin Oncol
; 41(22): 3839-3850, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290035
4.
Dosimetric impact of interfraction catheter movement and organ motion on MRI/CT guided HDR interstitial brachytherapy for gynecologic cancer.
Radiother Oncol
; 107(1): 112-6, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23333023